Topic
How common are GLP-1 side effects, really?
How common each side effect is, what the labels warn about, and where the lawsuits stand today.
Can You Drink Alcohol on Semaglutide? What Labels and Trials SayThe Ozempic and Wegovy labels list contraindications for MTC/MEN 2 and hypersensitivity, and interactions with insulin and oral drugs. In a 26-week trial, semaglutide cut heavy drinking days by 41.1 vs 26.4 percentage points.Does Semaglutide Cause Muscle Loss?Some of the weight lost on semaglutide is lean tissue, which is true of nearly all weight loss, but the size of that share and what changes it are the parts worth understanding.Does Zepbound Cause Hair Loss? What the Label and Studies ShowHair loss is a listed adverse reaction on the Zepbound label, reported by 4–5% of patients in trials versus 1% on placebo, mostly women, and the label ties it to weight reduction. Causality has not been established.How to Stop Nausea from Semaglutide: Timing, Diet, and Warning SignsNausea on semaglutide is common, peaks during the first 4 to 5 weeks and during dose escalation, and usually resolves within 8 days. Slower eating, smaller low-fat meals, and small sips of fluid help; a prescriber can slow the dose schedule if needed.Mounjaro Lawsuits: What's Alleged and Where Cases Stand in 2026Mounjaro is named in MDL 3094, the federal GLP-1 gastrointestinal injury litigation, and Zepbound is among Lilly's medicines at issue per its May 2026 brief. Nearly 3,000 gastroparesis suits were pending as of December 2025; a Daubert hearing was set for September 14–18, 2026.Mounjaro Side Effects: What the Label Reports and How OftenThe most common Mounjaro side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain; nausea reached 18% at the 15 mg dose in placebo-controlled trials. The label also carries a boxed warning about thyroid C-cell tumors seen in rats.Ozempic Face: What It Is, Why It Happens, and What You Can DoOzempic face is a colloquial term for the sunken, aged look that can follow rapid weight loss on semaglutide. It is not a medically recognized condition and poses no serious health risk, but options like fillers, skin-tightening procedures, and surgery can address the volume loss.Ozempic Lawsuits: Where the Two Federal MDLs Stand in 2026As of the JPML's September 1, 2026 report, 4,022 gastrointestinal-injury lawsuits are pending in MDL 3094 and 216 vision-loss (NAION) lawsuits in MDL 3163, both before Judge Karen S. Marston in Pennsylvania. No settlements have been announced in either docket.Semaglutide and Surgery: Anesthesia Risk and What to Tell Your TeamSemaglutide slows stomach emptying, so food can remain even after fasting. A 2024 multi-society guidance says most patients continue the drug before elective procedures; the FDA label says data are insufficient to recommend stopping, and patients should tell providers about planned procedures.Semaglutide Side Effects: Complete List of Common and Serious ReactionsThe most common semaglutide side effects are digestive: nausea affected 44% of adults on Wegovy 2.4 mg versus 16% on placebo. Serious risks include pancreatitis, gallbladder disease, kidney injury, and a rare eye condition called NAION.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.Zepbound and Alcohol: Label Warnings and Drinking EvidenceThe Zepbound and Mounjaro Drug Interactions sections cover insulin, sulfonylureas, and oral medications. A study of more than 120 million US health records linked tirzepatide to about half the rate of new alcohol use disorder diagnoses (HR 0.47), and a 42-person randomized trial is underway.Zepbound Side Effects: Complete List of What Trials ShowIn the label's main safety pool of 2,519 adults, digestive problems dominate: 56% had a GI reaction on each Zepbound dose versus 30% on placebo, and 4.8% to 6.7% stopped treatment over side effects. The boxed warning covers thyroid C-cell tumors seen in rats, not proven in humans.